Undifferentiated pleomorphic sarcoma
Undifferentiated pleomorphic sarcoma | |
---|---|
Other names | Pleomorphic myofibrosarcoma, high-grade myofibroblastic sarcoma, and high-grade myofibrosarcoma |
Micrograph of undifferentiated pleomorphic sarcoma (H&E stain) | |
Specialty | Oncology |
Causes | Unknown |
Prognosis | Guarded |
Frequency | Rare |
Undifferentiated pleomorphic sarcoma (UPS), also termed pleomorphic myofibrosarcoma,
The diagnosis of UPS initially included the malignant fibrous histiocytomas (MFH).
The majority of UPS tumors are highly aggressive, often recur after surgical removal, and often metastasize.
Presentation
UPS commonly presents as a deep-seated, rapidly enlarging, painless mass in individuals aged 50 to 70 years. These masses are rarely superficial lesions and rarely occur in the pediatric population.
Neoplastic fever
A review study conducted in China of 183 individuals with UPS reported that 7 (3.83%) individuals (age 51 to 73 years; median age 62.8 years) had a subtype of the paraneoplastic syndrome termed neoplastic fever, i.e. these individuals suffered continuous, disabling fevers. Their tumors were located within a thigh muscle (4 cases), the upper arm (2 cases), or the lower leg (1 case). Compared to 89 individuals (median age 59.1 years) with a similar distribution of their UPS tumors, individuals with the neoplastic syndrome had similar tumor recurrence rates (57.14% vs 53.93% for the two respective groups) but a lower metastasis rate (14.29% vs 44.94%) and a higher 3-year survival rate (85.71% vs 59.55%). Fever symptoms disappeared in all patients after surgical removal of their tumors. It is suggested that individuals with UPS and neoplastic fever have a more favorable prognosis than individuals with UPS that do not evidence such fevers.[7]
Pathology
UPS is a diagnosis of exclusion (a diagnosis reached by the process of elimination) because the histopathology of this disorder's tumors is non-specific. UPS tumor cells are undifferentiated (i.e. do not resemble any particular cell type) and pleomorphic (i.e. highly variable in size, shape, and/or color) when examined microscopically. Therefore, the diagnosis of UPS is commonly based on detecting a specific set of proteins that are expressed by UPS tumor cells but not by the cells of other undifferentiated and pleomorphic tumors or visa versa (see Diagnosis section).[11]
A study of 52 individuals found that their UPS tumor cells expressed on their
UPS tumors also show gene and chromosome abnormalities that further studies may find contribute to the development and/or progression of UPS. These abnormalities, which have not yet been reported to be helpful in diagnosing UPS, include the following. 1) Deletion and/or inactivation or the
Diagnosis
The diagnosis of UPS depends on finding non-specific, undifferentiated tumor cells that have features suggestive of UPS and not features of other tumor types that also consist of pleomorphic, undifferentiated cells. The features primarily involve the expression of certain proteins by the tumor cells. The identifying proteins for UPS tumor cells are given in the preceding section. Identification proteins for tumors that have been confused with UPS inlclude:[11]
- Pleomorphic leimyosarcoma: Desmin and h-caldesmon (i.e. high molecular form of caldesmon.[35]) proteins
- Pleomorphic rhabdomyosarcoma: Desmin and myogenin proteins.
- CDK4proteins.
- family of proteins.
- Melanoma: MLANA (i.e. melanoma antigen recognized by T cells 1 protein), S100, and PMEL (a product of the PMEL gene which is detected using an antibody termed HMB-45.[37]) proteins
Two other tumors that may be confused with UPS have microscopic histopathological and/or other features that help make this distinction. These tumors and features are:[11]
- Pleomorphic liposarcoma: At least some tumor cells have features of pleomorphic lipoblasts, i.e. variable shaped immature fat cells.
- Malignant peripheral nerve sheath tumor: Typically occurs in young children, often develops in a preexisting inoperable plexiform neurofibroma, and often associated with neural tissue. These tumors typically show undifferentiated, pleomorphic cells that are arranged in whorls, parallel bundles, or rosettes (i.e. circular arrangement resembling leaves in a flowering plant) and often contain large areas of necrosis (i.e. dead or dying cells).
Treatment and prognosis
The most often used treatment for localized (i.e. no metastases) UPS tumors is complete surgical removal with the object of leaving no tumor cells behind as evidenced by microscopic examinations.
In a retrospective study of 176 patients with localized UPS undergoing curative-intent treated with surgical resection or resection plus adjuvant treatment, disease-free survival rates at 120 months for patients with tumors in an extremity (leg or arm), heat/neck area, thorax, and abdomen/pelvis were about 70, 60, 50, and 0%, respectively; overall survival rates at 150 months for disease at these sites were about 90, 80, 75, and 35%, respectively. Patients who received surgery alone or surgery plus adjuvant treatment had disease-free survival rates of about 50 and 40%, respectively.[8] A retrospective analysis of 266 patients with UPS were treated with surgery alone (6% of cases), surgery plus radiotherapy (91% of cases), or surgery plus chemotherapy (3% of cases). Post-treatment local recurrences and metastases were observed in 15% and 38% of cases; 5- and 10-year overall survival rates were 60% and 48%, respectively; Overall median survival time were 10.1 years; and patients with tumors ≥10 cm in longest diameter had an almost 6-fold higher rate of developing metastases than patients with tumors 4 cm or smaller. Poorer prognoses were seen in older patients; in patients with tumors that were large-sized, deep-seated, and/or located in a leg; in patients that presented with metastases; and in patients who had positive surgical margins and/or developed local recurrences after surgery.[13] In another retrospective study, 203 individuals with UPS, 141 of whom had metastatic disease, were treated with regimens selected based on the severity of their disease. In this study, the overall 5 year survival rate was 4%. Patients with the most advanced disease had a median overall survival time 11 months.[39]
Immunotherapy
Recent studies have treated UPS by targeting the immune system with
References
- ^ S2CID 220565385.
- ^ PMID 32815307.
- S2CID 238357489.
- S2CID 221862064.
- ^ "What Is Cancer?". National Cancer Institute. 2007-09-17. Retrieved 2017-11-26.
- ^ S2CID 56178938.
- ^ PMID 34795527.
- ^ S2CID 212406069.
- ^ S2CID 204886468.
- PMID 33179614.
- ^ PMID 29220302.
- ^ PMID 28988646.
- ^ S2CID 198997759.
- ^ PMID 31819633.
- PMID 29097878.
- PMID 23678263.
- ^ PMID 32256920.
- ^ PMID 33254023.
- PMID 32670543.
- PMID 34400423.
- PMID 32311873.
- PMID 23805953.
- ^ S2CID 226270021.
- S2CID 244132643.
- S2CID 232773534.
- S2CID 52883298.
- PMID 29100075.
- PMID 33673145.
- PMID 34093545.
- ^ S2CID 3756473.
- ^ PMID 31018952.
- PMID 30281149.
- PMID 31128216.
- S2CID 231908606.
- PMID 10800398.
- S2CID 9053425.
- S2CID 20167145.
- ^ PMID 28499583.
- PMID 28391775.
- S2CID 212405175.
- PMID 31900276.
- PMID 32664595.
- PMID 28662235.
- PMID 30249211.